References
- Burrows B, Kettel LJ, Niden AH, et al. Patterns of cardiovascular dysfunction in chronic obstructive lung disease. N Engl J Med 1972; 286(17): 912–8
- Monreal M, Ruiz J, Salvador R, et al. Recurrent pulmonary embolism: a prospective study. Chest 1989; 95(5): 976–9
- Reeves JT, Grover RF, McMurtry I, et al. Pulmonary vascular reactivity. Deckers, Colorado, October 10–12, 1984. Bull Eur Physio- pathol Respir 1985; 21(6): 583–90
- Barritt DW, Jordan SC. Anticoagulant drugs in the treatment of pulmonary embolism: a controlled trial. Lancet 1960; 1(18): 1309–12
- Hull RD, Raskob GE, Hirsh J, et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med 1986; 315(18): 1109–14
- Formanek G, Frech RS, Amplatz K. Arterial thrombus formation during clinical percutaneous catheterization. Circulation 1970; 41(5): 833–9
- Grayburn PA, Willard JE, Brickner ME, et al. In vivo thrombus formation on a guide- wire during intravascular ultrasound imaging: evidence for inadequate heparinization. Cathet Cardiovasc Diagn 1991; 23(2): 141–3
- Wheeler AP, Jaquiss RD, Newman JH. Physician practices in the treatment of pulmonary embolism and deep venous thrombosis. Arch Intern Med 1988; 148(6): 1321–5
- Brandjes DP, Heijboer H, Buller HR, et al. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis. N Engl J Med 1992; 327(21): 1485–9
- UPET investigators. The Urokinase Pulmonary Embolism Trial: a national cooperative study. Circulation 1973: 47(4 Suppl 2): 1–108
- UPET investigators. Urokinase-streptokinase embolism trial: phase II results. A cooperative study. JAMA 1974; 229(12): 1606–13
- Sharma GV. Rationale for aggressive management of pulmonary embolism using thrombolytic agents. In: Comerota AJ, ed. Latest concepts and management of acute venous thromboembolic disease. Coronado, Calif: Abbott Symposium, 1992: 20–4
- Comerota AJ, Aldridge SC. Thrombolytic therapy for deep venous thrombosis: a clinical review. Can J Surg 1993; 36(4): 359–64
- Sharma GV, Folland ED, McIntyre KM. Long-term hemodynamic benefit of thrombolytic therapy in pulmonary embolic disease. J Am Coll Cardiol 1990; 15(2): 65A
- Feied CF. Pulmonary chest pain, cor pulmonale, and pulmonary embolism. In: Gibler WB, Aufderheide TP eds. Emergency cardiac care. St Louis: Mosby-Year Book, 1994
- Collins R, Scrimgeour A, Yusuf S, et al. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin: overview of results of randomized trials in general, orthopedic, and urologie surgery. N Engl J Med 1988; 318(18): 1162–73
- NI H Consensus Development Statement. Prevention of venous thrombosis and pulmonary embolism. JAMA 1986; 256(6): 744–9
- Kessler CM. Anticoagulation and thrombolytic therapy: practical considerations. Chest 1989: 95(5 Suppl): 245–56S
- Kessler CM. The pharmacology of aspirin, heparin, coumarin, and thrombolytic agents: implications for therapeutic use in cardiopulmonary disease. Chest 1991: 99(4 Suppl): 97–112S
- Ducas J, Prewitt RM. Pathophysiology and therapy of right ventricular dysfunction due to pulmonary embolism. Cardiovasc Clin 1987; 17(2): 191–202
- Feied CF. Pulmonary embolism. In: Rosen P, Barkin RM, eds. Emergency medicine: concepts and clinical practice. 3d ed. St Louis: Mosby-Year Book, 1992: 1285–1311
- Goldhaber SZ, Kessler CM, Heit J, et al. Randomised controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism. Lancet 1988; 2(8606): 293–8
- Prewitt RM, Hoy C, Kong A, et al. Thrombolytic therapy in canine pulmonary embolism: comparative effects of urokinase and recombinant tissue plasminogen activator. Am Rev Respir Dis 1990; 141(2): 290–5
- Agnelli G, Parise P. Bolus thrombolysis in venous thromboembolism. Chest 1992: 101 (4 Suppl): 172–182S
- Heit J. Thrombolytic agent dosage for pulmonar)? embolism: current research and clinical experience. In: Comerota AJ, ed,12 pp 24–33